Venient Fx Pancreatic Endocrine Function Comprehensive
Test Description
Venient Fx Pancreatic Endocrine Function Comprehensive is a disruptive, non-invasive test that provides comprehensive information on pancreatic endocrine function.
It is based on routine blood and urine analysis and is powered by both proprietary machine learning and public algorithms, and provides highly accurate broad diagnostic information, including the likelihood of insulin resistance, pre-diabetes and diabetes mellitus (DM), and provides comprehensive information. It also calculates the 7.5-year risk (%) of developing diabetes mellitus (DM).
It is based on the combination of different modules, such as the adult treatment panel III (ATP-III), the triglyceride and glucose index (TyG index), the homeostatic model assessment for insulin resistance (HOMA-IR), the HOMA-2 and the Quantitative insulin sensitivity check index (QUICKI). In addition, it also includes other determinations for the evaluation of renal function.
It is an Evidence Based Laboratory Medicine (EBML) test developed not only in accordance with the guidelines of the American Association of Clinical Endocrinology (AACE) and the American Diabetes Association (ADA), but also incorporating the latest scientific findings.
Screening recommendations
The United States Preventative Services Task Force (USPSTF) recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who are overweight or obese.
However, Kience Inc. Venient Fx Pancreatic Endocrine Function Comprehensive test to treat patients with symptoms, signs or suspected disease: type 1 diabetes mellitus, type 2 diabetes mellitus, overweight, obesity, sedentary lifestyle, abdominal obesity, metabolic syndrome, Cushing's syndrome, prolonged exposure to systemic corticosteroids, or gestational diabetes.
Intended Use
The target population for the Venient Fx Pancreatic Endocrine Function Comprehensive test is patients with symptoms, signs or suspicion of disease: type 1 diabetes mellitus, type 2 diabetes mellitus, autoimmune diabetes, obesity, sedentary lifestyle, abdominal obesity, metabolic syndrome, Cushing's syndrome, prolonged exposure to systemic corticosteroids or gestational diabetes.
Sample Clinical Vignette
A 50-year-old female with sedentary lifestyle and dyslipidemia presented for medical evaluation after a 3-month history of polyuria, polydipsia and polyphagia. She explained progressive blurred vision, numbness in feet and urinary tract infections. Physical exam revealed abdominal obesity, high blood pressure (165/95 mmHg) and altered vibrotactile sensitivity of lower limbs. Serum and urine are submitted to determine the risk of glucose-related diseases, such as diabetes and insulin resistance.
Required Laboratory Determinations
Serum Sterols & Fatty Acids —Total Cholesterol, HDL-Cholesterol, Cholesterol non-HDL, LDL-Cholesterol, VLDL-Cholesterol, Triglycerides—; Serum Hormones —Insulin—; Other Serum Analytes —Serum Creatinine, Glucose, Glycated Hemoglobin (HbA1c)—; Other Urine Analytes —Urine Albumin, Urine Creatinine—; Urinalysis –Density, pH, White Blood Cells, Nitrites, Protein, Glucose, Ketones, Urobilinogen, Urobilin, Red Blood Cells, Urine Sediment—.